Drug Profile


Alternative Names: Amlodipine besilate/valsartan; Amlodipine besylate/valsartan; Dafiro; Exforge; VAA489; Valsartan/amlodipine

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Ischaemic heart disorder therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 01 Apr 2015 Generic equivalent available in USA for Hypertension
  • 08 May 2012 Ipsen terminates its licence for amlodipine/valsartan in France
  • 31 May 2010 Novartis completes a phase III trial in Hypertension in China, Philippines and Romania
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top